ロード中...
Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan
BACKGROUND: Although blinatumomab, a bispecific T cell engaging antibody, exhibits high clinical response rates in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin’s lymphoma (B-NHL), it still has some limitations because of its short half-...
保存先:
| 出版年: | J Hematol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5322661/ https://ncbi.nlm.nih.gov/pubmed/28228105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0397-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|